KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash & Current Investments (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Cash & Current Investments for 6 consecutive years, with $747.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments rose 25.19% year-over-year to $747.9 million, compared with a TTM value of $747.9 million through Dec 2025, up 25.19%, and an annual FY2025 reading of $747.9 million, up 25.19% over the prior year.
  • Cash & Current Investments was $747.9 million for Q4 2025 at Recursion Pharmaceuticals, up from $663.0 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $747.9 million in Q4 2025 and bottomed at $219.1 million in Q1 2021.
  • Average Cash & Current Investments over 5 years is $483.5 million, with a median of $475.3 million recorded in 2023.
  • The sharpest move saw Cash & Current Investments surged 132.47% in 2022, then plummeted 36.87% in 2024.
  • Year by year, Cash & Current Investments stood at $516.6 million in 2021, then grew by 6.7% to $551.2 million in 2022, then fell by 28.37% to $394.8 million in 2023, then soared by 51.32% to $597.4 million in 2024, then grew by 25.19% to $747.9 million in 2025.
  • Business Quant data shows Cash & Current Investments for RXRX at $747.9 million in Q4 2025, $663.0 million in Q3 2025, and $528.2 million in Q2 2025.